Xenon Pharmaceuticals Inc.

This study is testing whether an investigational medicine called azetukalner can help reduce depressive symptoms in adults with bipolar I or II disorder. About 400 participants will be randomly assigned to receive either the study drug or a placebo for 6 weeks. Researchers will m…

This study is testing whether a new oral medication called azetukalner can help reduce symptoms in adults with moderate-to-severe major depression. About 450 participants will be randomly assigned to receive either the active drug or a placebo pill for 6 weeks, and neither they n…

This study is testing whether adding an investigational drug called XEN1101 to a person's current anti-seizure medications can better control severe, full-body convulsive seizures. It will involve about 160 people aged 12 and older who have generalized epilepsy and still experien…

This Phase 3 trial is testing whether adding the investigational drug XEN1101 to a person's current seizure medications can safely reduce the number of focal seizures they experience. The study will involve about 360 adults with focal epilepsy who are still having seizures despit…

This study is testing whether a new oral medicine called azetukalner can help reduce symptoms in adults with moderate-to-severe major depression. About 450 participants will be randomly assigned to receive either the real medicine or a placebo pill for 6 weeks, and neither they n…